The types segment classifies pharmacokinetic investigations into in vitro, in vivo, in silico, and physiologically based PK modeling sub‑categories. In vitro assays, such as microsomal stability and transporter studies, occupy a modest portion of the market, typically 15%, as they provide rapid, low‑cost insights into metabolic pathways. In vivo studies, involving animal or human subjects, dominate with about 55% of spending, reflecting the extensive resources required for full PK profiling and bioavailability assessments. In silico approaches, including quantitative structure‑activity relationship (QSAR) and machine‑learning predictions, have grown to roughly 20% of the market, driven by advancements in computational power and data integration. Finally, physiologically based PK (PBPK) modeling, which combines physiological parameters with drug‑specific data, accounts for the remaining 10%, supporting dose‑selection and drug‑drug interaction forecasts. These type categories collectively define the market taxonomy, highlighting where research funding and technology adoption are concentrated.